TScan Therapeutics (TCRX) Enterprise Value (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Enterprise Value of -$128.1 million for Q1 2026, up 49.12% year-over-year from -$85.9 million in Q1 2025, and up 15.98% quarter-over-quarter from -$152.4 million in Q4 2025.
TScan Therapeutics (TCRX) Enterprise Value (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Enterprise Value for 7 consecutive years, with -$128.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 49.12% year-over-year to -$128.1 million; the TTM figure through Mar 2026 stood at -$128.1 million (up 49.12% YoY), while the FY2025 annual figure was -$152.4 million, up 47.47% from the prior year.
- Enterprise Value grew to -$128.1 million in Q1 2026 per TCRX's latest filing, from -$152.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$95.6 million in Q1 2023 and bottomed at -$297.7 million in Q2 2024.
- Historically, Enterprise Value has averaged -$187.8 million across 5 years, with a median of -$184.5 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 70.26% — and 2026, when it jumped 49.12%.
- TScan Therapeutics' Enterprise Value stood at -$120.0 million in 2022, then plunged by 60.0% to -$192.0 million in 2023, then tumbled by 51.06% to -$290.1 million in 2024, then soared by 47.47% to -$152.4 million in 2025, then gained by 15.98% to -$128.1 million in 2026.
- Business Quant data shows TCRX's Enterprise Value at -$128.1 million in Q1 2026, -$152.4 million in Q4 2025, and -$184.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | TScan Therapeutics | 101.63 Mn | 101.63 Mn | - | -100.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -100.20 Mn |
| Mar 31, 2026 | -128.06 Mn |
| Dec 31, 2025 | -152.41 Mn |
| Sep 30, 2025 | -184.45 Mn |
| Jun 30, 2025 | -218.05 Mn |
| Mar 31, 2025 | -251.69 Mn |
| Dec 31, 2024 | -290.11 Mn |
| Sep 30, 2024 | -271.12 Mn |
| Jun 30, 2024 | -297.68 Mn |
| Mar 31, 2024 | -162.78 Mn |
| Dec 31, 2023 | -192.04 Mn |
| Sep 30, 2023 | -215.42 Mn |
| Jun 30, 2023 | -208.84 Mn |
| Mar 31, 2023 | -95.61 Mn |
| Dec 31, 2022 | -120.03 Mn |
| Sep 30, 2022 | -137.31 Mn |
| Jun 30, 2022 | -125.60 Mn |
| Mar 31, 2022 | -140.84 Mn |
| Dec 31, 2021 | -161.41 Mn |
| Sep 30, 2021 | -182.31 Mn |